Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown
cause. Approximately 5,000 people are diagnosed with IPF in the UK every year. People …

Randomised controlled clinical trials are fundamental in medicine to develop new effective
drugs and new therapeutic regimens and are the strength of evidence-based medicine …

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …

Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown etiology with an
unfavorable outcome from progressively deteriorating respiratory function, leading ultimately …

Idiopathic pulmonary fibrosis (IPF) is a rare disease characterized by chronic, progressive,
and irreversible interstitial lung fibrosis of unknown cause [1, 2]. Main symptoms and signs …

Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic disease of the lung of
unknown etiology that affects approximately 150,000 patients in the United States. It carries …

Idiopathic pulmonary fibrosis (IPF) is a common form of interstitial lung disease and usually
results in progressive respiratory insufficiency and death. Steady progress has been made …

Background Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with
high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies …

Idiopathic pulmonary fibrosis (IPF) is a parenchymal lung disease characterized by
progressive interstitial fibrosis. The clinical course of IPF can be unpredictable and may be …

Background To date, no management approach has proven to be efficacious for the
treatment of idiopathic pulmonary fibrosis (IPF). Consequently, therapeutic options remain …